$ARCT
Arcturus Therapeutics Holdings Inc.

2024 Q1 Form 10-K Financial Statement

#000095017024031156 Filed on March 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $38.01M $33.99M $166.8M
YoY Change -52.65% -78.8% -19.03%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $14.85M $12.51M $52.87M
YoY Change 7.91% 5.46% 14.76%
% of Gross Profit
Research & Development $53.57M $36.62M $192.1M
YoY Change 3.49% 35.73% 30.04%
% of Gross Profit
Depreciation & Amortization $904.0K $815.0K $2.957M
YoY Change 56.4% 47.91% 93.65%
% of Gross Profit
Operating Expenses $68.42M $49.13M $245.0M
YoY Change 4.42% 26.48% 26.41%
Operating Profit -$30.41M -$78.21M
YoY Change -306.11% -742.24%
Interest Expense $3.963M $6.827M $16.36M
YoY Change 84.41% -342.95% -1167.32%
% of Operating Profit
Other Income/Expense, Net $4.016M $16.59M
YoY Change 62.13% -4050.24%
Pretax Income -$26.45M -$8.311M -$27.89M
YoY Change -152.01% -107.01% -362.03%
Income Tax $400.0K $262.0K $1.835M
% Of Pretax Income
Net Earnings -$26.82M -$8.573M -$29.73M
YoY Change -152.84% -107.31% -417.95%
Net Earnings / Revenue -70.55% -25.22% -17.82%
Basic Earnings Per Share -$1.00 -$1.12
Diluted Earnings Per Share -$1.00 -$0.32 -$1.12
COMMON SHARES
Basic Shares Outstanding 26.92M 26.72M 26.63M
Diluted Shares Outstanding 26.88M 26.63M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $288.4M $292.0M $292.0M
YoY Change -12.06% -25.49% -25.49%
Cash & Equivalents $288.4M $292.0M $292.0M
Short-Term Investments
Other Short-Term Assets $60.34M $62.52M $62.52M
YoY Change 1358.42% 619.79% 619.79%
Inventory
Prepaid Expenses
Receivables $27.06M $32.06M $32.06M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $375.8M $386.6M $386.6M
YoY Change -11.49% -4.15% -4.15%
LONG-TERM ASSETS
Property, Plant & Equipment $11.76M $12.43M $40.93M
YoY Change -6.9% 0.1% -8.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.885M $1.885M $1.885M
YoY Change -10.92% -9.98% -9.98%
Total Long-Term Assets $43.06M $42.81M $42.81M
YoY Change -7.01% -9.02% -9.02%
TOTAL ASSETS
Total Short-Term Assets $375.8M $386.6M $386.6M
Total Long-Term Assets $43.06M $42.81M $42.81M
Total Assets $418.8M $429.4M $429.4M
YoY Change -11.05% -4.66% -4.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.144M $5.279M $5.279M
YoY Change -52.73% -29.13% -29.13%
Accrued Expenses $34.77M $31.88M $31.88M
YoY Change 7.67% 5.45% 5.45%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $115.4M $81.99M $78.86M
YoY Change 28.07% -35.43% -37.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $39.45M $497.0K $68.90M
YoY Change 2181.49% -82.28% 29.78%
Total Long-Term Liabilities $39.45M $497.0K $68.90M
YoY Change 2181.49% -82.28% 29.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $115.4M $81.99M $78.86M
Total Long-Term Liabilities $39.45M $497.0K $68.90M
Total Liabilities $154.9M $150.9M $147.8M
YoY Change 9.36% -16.21% -17.95%
SHAREHOLDERS EQUITY
Retained Earnings -$394.7M -$367.9M
YoY Change 37.33% 8.81%
Common Stock $27.00K $27.00K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $264.0M $278.5M $281.6M
YoY Change
Total Liabilities & Shareholders Equity $418.8M $429.4M $429.4M
YoY Change -11.05% -4.66% -4.66%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$26.82M -$8.573M -$29.73M
YoY Change -152.84% -107.31% -417.95%
Depreciation, Depletion And Amortization $904.0K $815.0K $2.957M
YoY Change 56.4% 47.91% 93.65%
Cash From Operating Activities -$5.557M -$629.0K -$18.10M
YoY Change -84.51% -100.39% -156.57%
INVESTING ACTIVITIES
Capital Expenditures $240.0K $875.0K $2.901M
YoY Change -65.27% -77.02% -62.45%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$240.0K -$875.0K -$2.901M
YoY Change -65.27% -77.02% -62.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.188M -18.66M -24.09M
YoY Change -108.0% 735.89% 742.5%
NET CHANGE
Cash From Operating Activities -5.557M -629.0K -18.10M
Cash From Investing Activities -240.0K -875.0K -2.901M
Cash From Financing Activities 2.188M -18.66M -24.09M
Net Change In Cash -3.609M -20.16M -45.09M
YoY Change -94.35% -113.07% -310.61%
FREE CASH FLOW
Cash From Operating Activities -$5.557M -$629.0K -$18.10M
Capital Expenditures $240.0K $875.0K $2.901M
Free Cash Flow -$5.797M -$1.504M -$21.00M
YoY Change -84.14% -100.96% -186.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001768224
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-38942
CY2023 dei Entity Registrant Name
EntityRegistrantName
ARCTURUS THERAPEUTICS HOLDINGS INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
32-0595345
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
10628 Science Center Drive
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 250
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2023 dei City Area Code
CityAreaCode
858
CY2023 dei Local Phone Number
LocalPhoneNumber
900-2660
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023 dei Trading Symbol
TradingSymbol
ARCT
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
false
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
692400000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26915243
CY2023 dei Auditor Firm
AuditorFirmId
42
CY2023 dei Auditor Name
AuditorName
Ernst & Young, LLP
CY2023 dei Auditor Location
AuditorLocation
San Diego, California
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
292005000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
391883000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
55000000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
32064000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2764000
CY2023Q4 arct Prepaid Expenses And Other Receivables
PrepaidExpensesAndOtherReceivables
7521000
CY2022Q4 arct Prepaid Expenses And Other Receivables
PrepaidExpensesAndOtherReceivables
8686000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
386590000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
403333000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12427000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12415000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28500000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
32545000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1885000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2094000
CY2023Q4 us-gaap Assets
Assets
429402000
CY2022Q4 us-gaap Assets
Assets
450387000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5279000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7449000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31881000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30232000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
60655000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
44829000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
28648000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
81989000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
126984000
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
42496000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
20071000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25907000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30216000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
497000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2804000
CY2023Q4 us-gaap Liabilities
Liabilities
150889000
CY2022Q4 us-gaap Liabilities
Liabilities
180075000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26828000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26828000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26555000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26555000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
27000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
27000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
646352000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
608426000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-367866000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-338141000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
278513000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
270312000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
429402000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
450387000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
166799000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
205999000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12359000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
192133000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
147751000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
173760000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
52871000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
46071000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
41451000
CY2023 us-gaap Operating Expenses
OperatingExpenses
245004000
CY2022 us-gaap Operating Expenses
OperatingExpenses
193822000
CY2021 us-gaap Operating Expenses
OperatingExpenses
215211000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-78205000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
12177000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-202852000
CY2022 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-515000
CY2021 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
515000
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-229000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-598000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
584000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
16591000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-420000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1921000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
33953000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27890000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
10644000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-203674000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1835000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1295000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-29725000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
9349000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-203674000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.12
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.35
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.74
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.12
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.35
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.74
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26628000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26445000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26317000
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26628000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27093000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26317000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-29725000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
9349000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-203674000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29725000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
9349000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-203674000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
396553000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28915000
CY2021 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
5000000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
902000
CY2021 arct Stock Issued During Period Value Under Equity Plan
StockIssuedDuringPeriodValueUnderEquityPlan
515000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-203674000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
228211000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
30611000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1730000
CY2022 arct Stock Issued During Period Value Under Equity Plan
StockIssuedDuringPeriodValueUnderEquityPlan
411000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
9349000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
9349000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
270312000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34649000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2668000
CY2023 arct Stock Issued During Period Value Under Equity Plan
StockIssuedDuringPeriodValueUnderEquityPlan
609000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-29725000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
278513000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-29725000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
9349000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-203674000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2957000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1527000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1193000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
34649000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
30611000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
28915000
CY2021 arct Acquired In Process Research And Development Expense
AcquiredInProcessResearchAndDevelopmentExpense
5000000
CY2022 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-515000
CY2021 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
515000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
33953000
CY2023 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-90000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-375000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
577000
CY2023 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-502000
CY2022 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-2173000
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1990000
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
29300000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-603000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1242000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1165000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3584000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2333000
CY2023 arct Increase Decrease Operating Lease Right Of Use Asset
IncreaseDecreaseOperatingLeaseRightOfUseAsset
-4045000
CY2022 arct Increase Decrease Operating Lease Right Of Use Asset
IncreaseDecreaseOperatingLeaseRightOfUseAsset
-3264000
CY2021 arct Increase Decrease Operating Lease Right Of Use Asset
IncreaseDecreaseOperatingLeaseRightOfUseAsset
-1392000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2238000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3112000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-769000
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-588000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
9443000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4134000
CY2023 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
38606000
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-14694000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
32794000
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4309000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4477000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1351000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18099000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
31993000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-135043000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2901000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7726000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3406000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2901000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7726000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3406000
CY2023 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
20000000
CY2021 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
46599000
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2668000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1730000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
902000
CY2023 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
609000
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
411000
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
515000
CY2023 us-gaap Repayments Of Debt
RepaymentsOfDebt
47364000
CY2022 us-gaap Repayments Of Debt
RepaymentsOfDebt
5000000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-24087000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2859000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
48016000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-45087000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
21408000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-90433000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
393977000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
372569000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
463002000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
348890000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
393977000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
372569000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
2127000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
813000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
684000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
30191000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1828000
CY2021 arct Acquisition Of Research And Development In Process Through Issuance Of Common Stock
AcquisitionOfResearchAndDevelopmentInProcessThroughIssuanceOfCommonStock
5000000
CY2023 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
68000
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
573000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
53000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-367900000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-338100000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
348900000
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1900000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2100000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Significant Customers</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents. The Company limits its exposure to credit loss by placing its cash and cash equivalents with high credit quality financial institutions in instruments with short maturities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customers that comprised </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the total accounts receivable balance at December 31, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023, the Company’s top </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customers collectively represented </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Company’s total revenue. For the year ended December 31, 2022, the Company's top </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">five</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customers collectively represented </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Company’s total revenue. For the year ended December 31, 2021, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">four</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customers that collectively represented </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Company’s total revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
CY2023 us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
0
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
0
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
0
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
292005000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
391883000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
370492000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
55000000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1885000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2094000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2077000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
348890000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
393977000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
372569000
CY2023 us-gaap Dividends
Dividends
0
CY2022 us-gaap Dividends
Dividends
0
CY2022Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
2764000
CY2023 arct Contract With Customer Asset Additions
ContractWithCustomerAssetAdditions
205746000
CY2023 arct Contract With Customer Asset Deductions
ContractWithCustomerAssetDeductions
-176446000
CY2023Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
32064000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
48719000
CY2023 arct Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
205405000
CY2023 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-166799000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
87325000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5918000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4038000
CY2023Q4 arct Accrued Cystic Fibrosis Foundation Liability
AccruedCysticFibrosisFoundationLiability
7633000
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
641000
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
1295000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4309000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3884000
CY2023Q4 arct Clinical Trial Accruals Current
ClinicalTrialAccrualsCurrent
2333000
CY2022Q4 arct Clinical Trial Accruals Current
ClinicalTrialAccrualsCurrent
4531000
CY2023Q4 arct Vinbiocare Contractual Liabilities
VinbiocareContractualLiabilities
2514000
CY2022Q4 arct Vinbiocare Contractual Liabilities
VinbiocareContractualLiabilities
7468000
CY2023Q4 arct Other Accrued Research And Development Expenses
OtherAccruedResearchAndDevelopmentExpenses
8533000
CY2022Q4 arct Other Accrued Research And Development Expenses
OtherAccruedResearchAndDevelopmentExpenses
9016000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31881000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30232000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21167000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18198000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8740000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5783000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12427000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12415000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3000000.0
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1500000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1200000
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
800000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3700000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1300000
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
174000
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1835000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1295000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1835000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1295000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6622740
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
34.78
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10721000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2140206
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
27.38
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
237820
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
11.26
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
553999
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
34.31
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7971127
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
33.55
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
53295000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3700692
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
38.04
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y7M6D
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
31142000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
7971127
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
33.55
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y10M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
53295000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
78800000
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
35300000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
39200000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
28400000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4300000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1600000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3600000
CY2023Q3 us-gaap Share Price
SharePrice
34.92
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
34649000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
30611000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28915000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-27890000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
10644000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-203674000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-27890000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
10644000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-203674000
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
1246000
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
1121000
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
589000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.019
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.072
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.062
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.025
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.161
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.004
CY2023 arct Effective Income Tax Rate Reconciliation Nondeductible Expense Officers Compensation
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation
-0.074
CY2022 arct Effective Income Tax Rate Reconciliation Nondeductible Expense Officers Compensation
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation
0.218
CY2021 arct Effective Income Tax Rate Reconciliation Nondeductible Expense Officers Compensation
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation
-0.011
CY2023 arct Effective Income Tax Rate Reconciliation Research And Development Credits
EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits
0.20
CY2022 arct Effective Income Tax Rate Reconciliation Research And Development Credits
EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits
-0.403
CY2021 arct Effective Income Tax Rate Reconciliation Research And Development Credits
EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentCredits
0.029
CY2023 arct Effective Income Tax Rate Reconciliation Uncertain Tax Position
EffectiveIncomeTaxRateReconciliationUncertainTaxPosition
-0.024
CY2022 arct Effective Income Tax Rate Reconciliation Uncertain Tax Position
EffectiveIncomeTaxRateReconciliationUncertainTaxPosition
0.09
CY2021 arct Effective Income Tax Rate Reconciliation Uncertain Tax Position
EffectiveIncomeTaxRateReconciliationUncertainTaxPosition
-0.004
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.002
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.126
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.017
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.365
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.094
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.267
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.003
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.01
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.002
CY2023 arct Effective Income Tax Rate Reconciliation Other Permanent Differences
EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
-0.007
CY2022 arct Effective Income Tax Rate Reconciliation Other Permanent Differences
EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
0.004
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.067
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.122
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
19147000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
47866000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
10723000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
10460000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
943000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1420000
CY2023Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
7014000
CY2022Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
611000
CY2023Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
15961000
CY2022Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
9016000
CY2023Q4 us-gaap Deferred Tax Assets Equity Method Investments
DeferredTaxAssetsEquityMethodInvestments
2202000
CY2022Q4 us-gaap Deferred Tax Assets Equity Method Investments
DeferredTaxAssetsEquityMethodInvestments
2212000
CY2023Q4 arct Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
41971000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5646000
CY2022Q4 arct Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
19938000
CY2023Q4 arct Deferred Tax Assets Right Of Use Lease Liability
DeferredTaxAssetsRightOfUseLeaseLiability
7233000
CY2022Q4 arct Deferred Tax Assets Right Of Use Lease Liability
DeferredTaxAssetsRightOfUseLeaseLiability
8200000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
11618000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
7201000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
116812000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
106924000
CY2023Q4 arct Deferred Tax Liabilities Property Plant And Equipment And Intangible Assets
DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets
1184000
CY2022Q4 arct Deferred Tax Liabilities Property Plant And Equipment And Intangible Assets
DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets
475000
CY2023Q4 arct Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
6822000
CY2022Q4 arct Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
7826000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
8006000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
8301000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
108806000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
98623000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
108800000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
98600000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
10200000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1000000
CY2023 arct Net Operating Loss And Research And Development Credit Carryforwards Limitations On Cumulative Change In Ownership Minimum Percentage
NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage
0.50
CY2023 arct Net Operating Loss And Research And Development Credit Carryforwards Limitations On Cumulative Change In Ownership Period
NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod
P3Y
CY2023 arct Maximum Percentage Of Likelihood Of Uncertain Tax Position Recognized To Be Sustained
MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained
0.50
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2900000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2400000
CY2023 arct Unrecognized Tax Benefits Decreases Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions
100000
CY2022 arct Unrecognized Tax Benefits Decreases Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions
-500000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
600000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1000000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
3600000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2900000
CY2023Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2023 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4019000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3603000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3711000
CY2023Q4 arct Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
19572000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
36551000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6335000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
30216000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y2M12D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.048
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
5600000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
4700000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
1900000

Files In Submission

Name View Source Status
0000950170-24-031156-index-headers.html Edgar Link pending
0000950170-24-031156-index.html Edgar Link pending
0000950170-24-031156.txt Edgar Link pending
0000950170-24-031156-xbrl.zip Edgar Link pending
arct-20231231.htm Edgar Link pending
arct-20231231.xsd Edgar Link pending
arct-ex19_1.htm Edgar Link pending
arct-ex23_1.htm Edgar Link pending
arct-ex31_1.htm Edgar Link pending
arct-ex31_2.htm Edgar Link pending
arct-ex31_3.htm Edgar Link pending
arct-ex32_1.htm Edgar Link pending
arct-ex32_2.htm Edgar Link pending
arct-ex32_3.htm Edgar Link pending
arct-ex4_1.htm Edgar Link pending
arct-ex97_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img266266313_0.jpg Edgar Link pending
img266266313_1.jpg Edgar Link pending
img266266313_10.jpg Edgar Link pending
img266266313_11.jpg Edgar Link pending
img266266313_12.jpg Edgar Link pending
img266266313_13.jpg Edgar Link pending
img266266313_14.jpg Edgar Link pending
img266266313_15.jpg Edgar Link pending
img266266313_16.jpg Edgar Link pending
img266266313_17.jpg Edgar Link pending
img266266313_18.jpg Edgar Link pending
img266266313_19.jpg Edgar Link pending
img266266313_2.jpg Edgar Link pending
img266266313_20.jpg Edgar Link pending
img266266313_21.jpg Edgar Link pending
img266266313_22.jpg Edgar Link pending
img266266313_23.jpg Edgar Link pending
img266266313_24.jpg Edgar Link pending
img266266313_25.jpg Edgar Link pending
img266266313_26.jpg Edgar Link pending
img266266313_27.jpg Edgar Link pending
img266266313_28.jpg Edgar Link pending
img266266313_29.jpg Edgar Link pending
img266266313_3.jpg Edgar Link pending
img266266313_30.jpg Edgar Link pending
img266266313_4.jpg Edgar Link pending
img266266313_5.jpg Edgar Link pending
img266266313_6.jpg Edgar Link pending
img266266313_7.jpg Edgar Link pending
img266266313_8.jpg Edgar Link pending
img266266313_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
arct-20231231_htm.xml Edgar Link completed
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable